Skip to content

Neuromodulatory interventions for reducing neuropathic pain after spinal cord injury

NeuroStim+: Investigating the efficacy of neuromodulation to decrease the severity of neuropathic pain in individuals with a spinal cord injury

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12625000737437
Acronym
NeuroStim+
Enrollment
231
Registered
2025-07-11
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study aims to evaluate the efficacy of two promising treatments for reducing neuropathic pain in individuals with spinal cord injury - electroencephalography neurofeedback (EEG-NF) and transcranial direct current stimulation (tDCS) - delivered individually and in combination in 20 sessions over 5 weeks. EEG-NF trains individuals to self-regulate brainwave activity, with the goal of regulating neural patterns associated with neuropathic pain. tDCS involves the application of an electrical current via two electrodes (anode and cathode) to modulate cortical excitability in a safe and non-invasive manner. The primary hypotheses for 6 weeks post-randomisation are: (1) Participants receiving EEG-NF will report significantly lower pain severity compared to those not receiving EEG-NF. (2) Participants receiving active tDCS will report significantly lower pain severity compared to those receiving sham tDCS. (3) Participants receiving the combination of EEG-NF and active tDCS will report significantly lower pain severity compared to those receiving either EEG-NF or active tDCS.

Interventions

The investigational medical device in this clinical trial includes two devices, electroencephalography (EEG) neurofeedback and transcranial direct current stimulation (tDCS), evaluated individually and in combination. Group 1: EEG-NF + active tDCS Group 2: EEG-NF + sham tDCS Group 3: Active tDCS Group 4: Sham tDCS All interventions are home-based and self-administered by participants for 20 sessions over a 5-week period, with one session completed per day. Each session will last approximate

The investigational medical device in this clinical trial includes two devices, electroencephalography (EEG) neurofeedback and transcranial direct current stimulation (tDCS), evaluated individually and in combination. Group 1: EEG-NF + active tDCS Group 2: EEG-NF + sham tDCS Group 3: Active tDCS Group 4: Sham tDCS All interventions are home-based and self-administered by participants for 20 sessions over a 5-week period, with one session completed per day. Each session will last approximately 60 min for Groups 1 and 2, and 30 min for Groups 3 and 4. Adherence is assessed through automatic logging of device usage and completion data, which are uploaded in real time to a secure, study-specific dashboard accessible only to the research team. This system allows for continuous monitoring of session completion and engagement across all study arms. Active tDCS will be delivered using the Sooma Duo tDCS device. The device will be pre-programmed to provide active stimulation at 2 mA for the entire treatment session, with a gradual ramp-up to 2 mA at a rate of 0.1 mA/s at the beginning and a ramp-down to 0 mA at the same rate at the end of the tDCS session. Stimulation will be delivered through 5 × 5 cm circular rubber electrodes, prepared by soaking sponge pads in saline and securing them within the electrode perimeter. An impedance threshold of 50 kiloohms must be met for the stimulation to begin. If impedance exceeds this threshold, participants will be instructed to apply additional saline solution beneath the electrodes. Using a customized electrode montage, the anodal electrode will be placed on the vertex of the head and held in place using a 3D printed headset. The cathodal electrode will be positioned on the shoulder and kept in place with a shoulder band. The EEG neurofeedback intervention is based on brain-computer interface (BCI) technology. We will be using an OpenBCI system with 3D printed headset. OpenBCI products are used as open-source tools for BCI systems. This EEG headset will be completed by a customised software and gaming interface in Unity game engine (Unity Technologies, USA). Our game scenario provides neurofeedback in an interactive, goal-directed, virtual gaming environment. The EEG headset records brain activity from C1 and C2 electrode sites (over the sensorimotor cortex), with reference electrode placed on the left ear and ground electrode on the right ear. To set up, participants will insert two pre-soaked sponge electrodes into the C1 and C2 electrode holders, then place the headset on their head. They will then play a game on a Surface Pro tablet, where they will view a gaming object (rocket, jellyfish, bird, or plane) that moves based on changes in EEG rhythms. The EEG-NF protocol aims to suppress theta (4–7 Hz) and high-beta (20–30 Hz) bands, while reinforcing the sensorimotor rhythms (SMR, 10–15 Hz). When participants successfully regulate all three bands in the desired direction, the object of the game will move faster or higher, and the background colour will change to give participants visual feedback. At the end of each round, participants will receive feedback on their progress through points. Each EEG neurofeedback session will consist of 5 rounds of neurofeedback games, each lasting 2.5 minutes, with a 30-second break between rounds.

Sponsors

University of New South Wales
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Factorial
Primary purpose
Treatment

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

· Have a complete or incomplete cervical, thoracic, or lumbar spinal cord injury, · Can breathe independently, · More than 6 months post-injury, · Have had ongoing nerve (neuropathic) pain at or below your injury level for more than three months, · Have an average pain level of at least 4 out of 10 over the past week, · Have an endorsement of more than 2 items on a 7-item Spinal Cord Injury Pain Instrument (SCIPI), · Are 18 years of age or older, · Can read and understand English, · Able to fully engage in the NeuroStim+ intervention by self-administering the tDCS and EEG headsets or by receiving assistance from a caregiver., · Willing and able to complete one NeuroStim+ intervention session per day, for 20 days over a 5-week period.

Exclusion criteria

· Have implanted devices such as cardiac pacemaker, cochlear implant, or deep brain stimulation, · Have a personal history of seizures, or someone in their immediate family (such as a parent, sibling, or child) has experienced seizures, · Have a history of a serious head injury (e.g., concussion) or illness (e.g., stroke) resulting in brain damage, · Have metal inside the head including surgical clips or fragments from welding/metalwork, · Have a diagnosed neurological disorder associated with cognitive impairment (e.g., dementia), or a psychiatric disorder such as schizophrenia, · Have serious or unstable medical conditions, including uncontrolled hypertension or significant cardiovascular or vascular disease., · Are pregnant/lactating, · Are located outside of Australia.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026